![](https://endpts.com/wp-content/uploads/2018/02/GettyImages-842900884_master.jpg)
CEO Pascal Soriot via Getty Images
AstraZeneca's juggernaut PARP player Lynparza scoops up another dominant win in PhIII as the FDA adds a 'breakthrough' for Calquence
AstraZeneca’s oncology R&D group under José Baselga keeps churning out hits.
Wednesday morning the pharma giant and their partners at Merck parted the curtains on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.